WO1999061010A3 - Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound - Google Patents

Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound Download PDF

Info

Publication number
WO1999061010A3
WO1999061010A3 PCT/EP1999/003138 EP9903138W WO9961010A3 WO 1999061010 A3 WO1999061010 A3 WO 1999061010A3 EP 9903138 W EP9903138 W EP 9903138W WO 9961010 A3 WO9961010 A3 WO 9961010A3
Authority
WO
WIPO (PCT)
Prior art keywords
meiosis
stimulating compound
infertility
treatment
combination
Prior art date
Application number
PCT/EP1999/003138
Other languages
French (fr)
Other versions
WO1999061010A2 (en
Inventor
Christa Hegele-Hartung
Quoc-Lam Cam
Original Assignee
Schering Ag
Hegele Hartung Christa
Cam Quoc Lam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Hegele Hartung Christa, Cam Quoc Lam filed Critical Schering Ag
Priority to JP2000550470A priority Critical patent/JP2002516272A/en
Priority to AU54089/99A priority patent/AU5408999A/en
Priority to CA002333320A priority patent/CA2333320A1/en
Priority to EP99939972A priority patent/EP1098652A2/en
Priority to KR1020007013278A priority patent/KR20010043828A/en
Publication of WO1999061010A2 publication Critical patent/WO1999061010A2/en
Publication of WO1999061010A3 publication Critical patent/WO1999061010A3/en
Priority to NO20005954A priority patent/NO20005954L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising c-AMP-increasing compounds in low dose and at least one meiosis-stimulating compound for the treatment of infertility and to the use of low dose c-AMP-increasing compounds alone or in combination with at least one meiosis-stimulating compound to increase the rate of fertilization in a mammal and for the preparation of medicaments. The preferred c-AMP-increasing compound is Hypoxanthine. The meiosis-stimulating compound is FF-MAS (4,4-dimethyl-5alpha-cholest-8,14,24-trien-3beta-ol).
PCT/EP1999/003138 1998-05-26 1999-05-07 Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound WO1999061010A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000550470A JP2002516272A (en) 1998-05-26 1999-05-07 Fertility treatment with a compound that increases cAMP alone or in combination with at least one compound that stimulates meiosis
AU54089/99A AU5408999A (en) 1998-05-26 1999-05-07 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound
CA002333320A CA2333320A1 (en) 1998-05-26 1999-05-07 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound
EP99939972A EP1098652A2 (en) 1998-05-26 1999-05-07 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound
KR1020007013278A KR20010043828A (en) 1998-05-26 1999-05-07 Treatment of Infertility with cAMP-Increasing Compounds Alone or in Combination with at Least One Meiosis-Stimulating Compound
NO20005954A NO20005954L (en) 1998-05-26 2000-11-24 Treatment of infertility with cAMP-increasing compounds alone or in combination with at least one meiosis stimulant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98250177.7 1998-05-26
EP98250177 1998-05-26

Publications (2)

Publication Number Publication Date
WO1999061010A2 WO1999061010A2 (en) 1999-12-02
WO1999061010A3 true WO1999061010A3 (en) 2000-04-27

Family

ID=8234594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003138 WO1999061010A2 (en) 1998-05-26 1999-05-07 Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound

Country Status (7)

Country Link
EP (1) EP1098652A2 (en)
JP (1) JP2002516272A (en)
KR (1) KR20010043828A (en)
AU (1) AU5408999A (en)
CA (1) CA2333320A1 (en)
NO (1) NO20005954L (en)
WO (1) WO1999061010A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148234A0 (en) 1999-09-16 2002-09-12 Novo Nordisk As Composition for ivf
US6544166B1 (en) 1999-11-25 2003-04-08 Groendahl Christian Treatment of human infertility
AU1692901A (en) * 1999-11-25 2001-06-04 Novo Nordisk A/S Treatment of human infertility
AU3376501A (en) * 2000-02-25 2001-09-03 Novo Nordisk A/S Improvement of implantation rate
US20030153808A1 (en) * 2000-02-25 2003-08-14 Christa Hegele-Hartung Implantation rate using ff-mas
EP1272618A2 (en) 2000-04-06 2003-01-08 Novo Nordisk A/S Synchronization of the cytoplasmatic and nuclear maturation of oocytes in vitro
EP1147774A1 (en) * 2000-04-20 2001-10-24 Stichting Dienst Landbouwkundig Onderzoek Method for improving the quality of sperm for artificial insemination of animals
US20040224878A1 (en) * 2000-05-18 2004-11-11 Suna Cukurcam Fertilization of aged oocytes
EP1245572A1 (en) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
US7507707B2 (en) * 2001-12-14 2009-03-24 Laboratoires Serono Sa Methods of inducing ovulation using a non-polypeptide camp level modulator
AU2003203145A1 (en) * 2002-02-22 2003-09-09 Novo Nordisk A/S A transducer of mas signalling
EP2750692B1 (en) 2011-08-30 2016-08-03 Centre National De La Recherche Scientifique Protein complex comprising mcm8 and mcm9 proteins and their use
GB201117453D0 (en) * 2011-10-10 2011-11-23 Univ Dundee Improved sperm function/activity
CN108531447B (en) * 2018-04-13 2021-11-23 上海市生物医药技术研究院 Compound for regulating sperm motility and assisted reproduction and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196530A2 (en) * 1985-03-26 1986-10-08 CTA Finanz AG Agent and process for increasing growth, for optimizing fertility and for stimulating the immune system in humans and animals
WO1996000235A1 (en) * 1994-06-23 1996-01-04 Novo Nordisk A/S Sterol derivatives used for regulation of meiosis
WO1996027658A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
WO1998004366A1 (en) * 1996-07-26 1998-02-05 Cauldron Limited Partnership Removal of material by radiation applied at an oblique angle
US5882928A (en) * 1997-03-11 1999-03-16 Oocytechs Research Corporation In vitro maturation and fertilization of mammalian oocytes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196530A2 (en) * 1985-03-26 1986-10-08 CTA Finanz AG Agent and process for increasing growth, for optimizing fertility and for stimulating the immune system in humans and animals
WO1996000235A1 (en) * 1994-06-23 1996-01-04 Novo Nordisk A/S Sterol derivatives used for regulation of meiosis
WO1996027658A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
WO1998004366A1 (en) * 1996-07-26 1998-02-05 Cauldron Limited Partnership Removal of material by radiation applied at an oblique angle
US5882928A (en) * 1997-03-11 1999-03-16 Oocytechs Research Corporation In vitro maturation and fertilization of mammalian oocytes

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BYSKOV A G ET AL: "CHEMICAL STRUCTURE OF STEROLS THAT ACTIVATE OOCYTE MEIOSIS", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 374, no. 6522, 6 April 1995 (1995-04-06), pages 559 - 562, XP002043016, ISSN: 0028-0836 *
CARROLL J ET AL: "Effect of dibutyryl cyclic adenosine monophosphate on granulosa cell proliferation, oocyte growth and meiotic maturation in isolated mouse primary ovarian follicles cultured in collagen gels.", JOURNAL OF REPRODUCTION AND FERTILITY, (1991 MAY) 92 (1) 197-207., XP000874962 *
DIENHART, MARY K. ET AL: "Cyclic AMP reversal of hypoxanthine-arrested preimplantation mouse embryos is EDTA-dependent", ZYGOTE (1996), 4(2), 129-137, XP000874771 *
HARADA, M. ET AL: "Bovine oocytes from early antral follicles grow to meiotic competence in vitro: Effect of FSH and hypoxanthine.", THERIOGENOLOGY, (1997) VOL. 48, NO. 5, PP. 743-755., XP000874856 *
OTTESEN, JAN L. ET AL: "The effect of meiosis activating sterol (MAS) and some oxysterols on the resumption of meiosis in mouse oocytes cultured in vitro.", BIOLOGY OF REPRODUCTION, (1997) VOL. 56, NO. SUPPL. 1, PP. 97. MEETING INFO.: THIRTIETH ANNUAL MEETING OF THE SOCIETY FOR THE STUDY OF REPRODUCTION PORTLAND, OREGON, USA AUGUST 2-5, 1997, XP000874956 *
RUAN, BENFANG ET AL: "Sterols affecting meiosis: novel chemical syntheses and the biological activity and spectral properties of the synthetic sterols", J. LIPID RES. (1998), 39(10), 2005-2020, XP000874959 *
WARIKOO P K ET AL: "Hypoxanthine and cyclic adenosine 5'-monophosphate maintain meiotic arrest of rhesus monkey oocytes in vitro.", FERTILITY AND STERILITY, (1989 MAY) 51 (5) 886-9., XP000874960 *
WIERSMA A ET AL: "SPECIFIC PHOSPHODIESTERASE 3 INHIBITORS PREVENT THE RESUMPTION OF MEIOSIS IN MOUSE OOCYTES IN VITRO", BIOLOGY OF REPRODUCTION,US,ORLANDO, FL, vol. 56, no. SUPPL. 01, 1997, pages 91, XP000874782, ISSN: 0006-3363 *
WIERSMA, A. ET AL: "Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents", J. CLIN. INVEST. (1998), 102(3), 532-537, XP000874944 *

Also Published As

Publication number Publication date
WO1999061010A2 (en) 1999-12-02
CA2333320A1 (en) 1999-12-02
KR20010043828A (en) 2001-05-25
NO20005954D0 (en) 2000-11-24
JP2002516272A (en) 2002-06-04
AU5408999A (en) 1999-12-13
NO20005954L (en) 2000-11-24
EP1098652A2 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
CA2427227A1 (en) Lactam compound
IL212075A0 (en) Pharmaceutical compositions comprising a combination of a renin inhibitor and at least one therapeutic agent and uses thereof for the manufacture of medicaments for the prevention of, delay of progression of, or treatment of a disease
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
CA2289717A1 (en) Novel therapy for constipation
CA2274074A1 (en) Novel compounds with analgesic effect
CA2386690A1 (en) Pharmaceutical tramadol salts
NZ502280A (en) Combination therapy comprising atorvastatin and an antihypertensive agent
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CA2378469A1 (en) An oral solid composition comprising carbidopa, levodopa and entacapone
IL109579A0 (en) Bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
AU8188691A (en) The use of inositoltrisphosphate for the preparing of medicaments
WO2002016312A3 (en) NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
WO1998009599A3 (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
WO1996022305A3 (en) Modified peptides
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
UA42733C2 (en) Bis-naphthalimide derivatives and pharmaceutically acceptable acid addition salts thereof, pharmaceutical composition containing them showing cytotoxic activity
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
WO2000066550A8 (en) New compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999939972

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009505

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2333320

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09701026

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020007013278

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999939972

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007013278

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999939972

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007013278

Country of ref document: KR